Results 41 to 50 of about 1,502,489 (240)

Progress on Designing a Chemical Retinal Prosthesis

Frontiers in Cellular Neuroscience, 2022
The last major review of progress toward a chemical retinal prosthesis was a decade ago. Many important advancements have been made since then with the aim of producing an implantable device for animal testing.
Jiajia Wu, Corey M. Rountree, Sai-Siva Kare, Pradeep Kumar Ramkumar, John D. Finan, John B. Troy   +5 more
doaj   +1 more source

Dexamethasone Intravitreal Implant Is Active at the Molecular Level Eight Weeks after Implantation in Experimental Central Retinal Vein Occlusion

Molecules, 2022
Central retinal vein occlusion (CRVO) is a visually disabling condition resulting from a thrombus in the major outflow vessel of the eye. The inflammatory response in CRVO is effectively treated with a dexamethasone (DEX) intravitreal implant. Uncovering
Lasse Jørgensen Cehofski, Anders Kruse, Mads Odgaard Mæng, Benn Falch Sejergaard, Anders Schlosser, Grith Lykke Sorensen, Jakob Grauslund, Bent Honoré, Henrik Vorum   +8 more
doaj   +1 more source

Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]

, 2019
The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto, Greco A., La Cava M, Lambiase A, Limoli PG, Nebbioso M   +5 more
core   +1 more source

Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports [PDF]

, 2020
Introduction: Since vascular endothelial growth factor (VEGF) regulates several aspects of the central nervous system, particularly in dopaminergic neurons, VEGF inhibitors may be linked to Parkinson-like events and dementia, or variants of these ...
Avery, Bergvall, Caballero, Campochiaro, Cutroneo, de Jong, De Rossi, Evans, Ferrara, Ferrara, Kumar, Lim, Lindquist, McColl, Meyer, Robinson, Sanchez, Sharma, Sheikh, Simó, Steen, Storkebaum, Sultana, Thulliez, Tian, Trifirò, Ueta, Wong, Yasuhara, Ylä-Herttuala, Zachary   +30 more
core   +4 more sources

Ropivacaine vs tetracaine in topical anesthesia for intravitreal injection [PDF]

, 2015
Aim: The object of the study was to evaluate the long term efficacy and safety of ropivacaine 0,5% vs tetracaine 0,5% for topical anesthesia in intravitreal injection of dexamethasone in patients with diabetic macular edema (DME) and anti-vascular ...
COLLINI, Saul, PACELLA, Elena, PACELLA, FERNANDA, SALDUCCI, Mauro, SMALDONE, GIANPAOLO, Troisi, Fabiana, TURCHETTI, PAOLO   +6 more
core   +1 more source

Acute retinal necrosis following dexamethasone intravitreal implant (Ozurdex®) administration in an immunocompetent adult with a history of HSV encephalitis: a case report

BMC Ophthalmology, 2020
Background Dexamethasone intravitreal implants (0.7 mg) (Ozurdex®, Allergan Inc., Madison, NJ) are FDA approved for managing macular oedema (ME) of retinal vein occlusion (RVO).
Zhi-Yong Zhang, Xiu-Yun Liu, Tao Jiang
doaj   +1 more source

An eighteen-month follow-up study on the effects of intravitreal dexamethasone implant in diabetic macular edema refractory to anti-VEGF therapy [PDF]

, 2016
AIM: To evaluate the long-term efficacy and safety of dexamethasone implants in subjects affected by diabetic macular edema (DME) resistant to anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Thirty-two DME patients were enrolled.
Carnovale, Anna, Mastromatteo, Alessandra, Mollicone, Antonella, Pacella, Elena, Pacella, Fernanda, Romano, Maria Rosaria, Tarquini, Giovanna, Turchetti, Paolo   +7 more
core   +1 more source

Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant

Acta ophthalmologica, 2019
To investigate disorganization of retinal inner layers (DRIL) as a biomarker in eyes with diabetic macular oedema (DME) treated by intravitreal dexamethasone (DEX) implant.
Dinah Zur, Matias Iglicki, A. Sala-Puigdollers, J. Chhablani, M. Lupidi, S. Fraser-bell, T. S. Mendes, V. Chaikitmongkol, Z. Cebeci, Dolev Dollberg, C. Busch, A. Invernizzi, Z. Habot-Wilner, A. Loewenstein   +13 more
semanticscholar   +1 more source

Refractive change following pseudophakic vitrectomy: a retrospective review [PDF]

, 2008
Background To assess the occurrence and magnitude of refractive change in pseudophakic eyes undergoing 20 gauge pars plana vitrectomy without scleral buckling and to investigate possible aetiological factors.
Anthony Hildreth, CY Hu, David HW Steel, James Ng, JB Randleman, Jean-Pierre Danjoux, JR McEwan, JW Jeoung, L Zheng, M Shioya, O Cekic, O Findl, P Brazitikos, RV Campo, S Cisiecki, Sinead Byrne, T Eckert, T Oshika, Y Suzuki, YR Sharma   +19 more
core   +5 more sources

Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion–related macular edema: A systematic review and meta-analysis of randomized controlled trials

Indian Journal of Ophthalmology, 2019
This systematic review aimed to evaluate the effectiveness and safety of intravitreal dexamethasone (DEX) implant and intravitreal anti-vascular endothelial growth factor (VEGF) treatments for macular edema (ME) secondary to retinal vein occlusion (RVO),
Qiuming Hu, Haoyu Li, Wenhua Xu, Yi Du, Chao Ma, Jianfeng He   +5 more
doaj   +1 more source